KR101937279B1 - 고형 종양의 치료 방법 - Google Patents

고형 종양의 치료 방법 Download PDF

Info

Publication number
KR101937279B1
KR101937279B1 KR1020137027532A KR20137027532A KR101937279B1 KR 101937279 B1 KR101937279 B1 KR 101937279B1 KR 1020137027532 A KR1020137027532 A KR 1020137027532A KR 20137027532 A KR20137027532 A KR 20137027532A KR 101937279 B1 KR101937279 B1 KR 101937279B1
Authority
KR
South Korea
Prior art keywords
cells
methyl
cell
mcs
iron chelating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137027532A
Other languages
English (en)
Korean (ko)
Other versions
KR20140017619A (ko
Inventor
스티그 린데르
모르텐 프뤼크네스
롤프 라르손
Original Assignee
비보룩스 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비보룩스 아베 filed Critical 비보룩스 아베
Publication of KR20140017619A publication Critical patent/KR20140017619A/ko
Application granted granted Critical
Publication of KR101937279B1 publication Critical patent/KR101937279B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020137027532A 2011-03-21 2012-03-14 고형 종양의 치료 방법 Active KR101937279B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1100201-1 2011-03-21
SE1100201 2011-03-21
PCT/SE2012/000034 WO2012128689A1 (en) 2011-03-21 2012-03-14 Treatment of solid tumours

Publications (2)

Publication Number Publication Date
KR20140017619A KR20140017619A (ko) 2014-02-11
KR101937279B1 true KR101937279B1 (ko) 2019-01-10

Family

ID=46879602

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137027532A Active KR101937279B1 (ko) 2011-03-21 2012-03-14 고형 종양의 치료 방법

Country Status (20)

Country Link
US (2) US20140073645A1 (https=)
EP (1) EP2688569B1 (https=)
JP (1) JP6064215B2 (https=)
KR (1) KR101937279B1 (https=)
CN (1) CN103547268B (https=)
AU (1) AU2012231814B2 (https=)
BR (1) BR112013024211B1 (https=)
CA (1) CA2830081C (https=)
DK (1) DK2688569T3 (https=)
EA (1) EA025180B1 (https=)
ES (1) ES2681703T3 (https=)
HU (1) HUE039021T2 (https=)
IL (1) IL228411A (https=)
MX (1) MX2013010770A (https=)
PL (1) PL2688569T3 (https=)
PT (1) PT2688569T (https=)
SG (2) SG193494A1 (https=)
TR (1) TR201809040T4 (https=)
WO (1) WO2012128689A1 (https=)
ZA (1) ZA201307036B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10386983B2 (en) 2014-12-31 2019-08-20 Tsinghua University Electrostatic sensing device
KR20250178249A (ko) 2024-06-17 2025-12-26 서울대학교산학협력단 Vlx600을 포함하는 항균 또는 항진균용 조성물 및 세균 또는 진균 감염증의 예방 또는 치료용 약학적 조성물

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014046589A1 (en) * 2012-09-21 2014-03-27 Vivolux Ab Means and method for treating solid tumours
US12383518B2 (en) 2013-11-03 2025-08-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Disulfide-masked pro-chelator compositions and methods of use
US11504346B2 (en) 2013-11-03 2022-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Redox-activated pro-chelators
CN107847534B (zh) * 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
CN104997777A (zh) * 2015-07-24 2015-10-28 孔小乐 去铁酮的2比1锌络合物作为制备抗癌药物的应用
JP7103745B2 (ja) * 2015-10-05 2022-07-20 国立大学法人 岡山大学 癌幹細胞抑制剤、癌の転移又は再発の抑制剤並びに癌細胞の未分化マーカー発現抑制剤
CN108431003A (zh) * 2015-12-18 2018-08-21 威沃路克斯股份公司 含有吲哚衍生物的药物组合物、其制备方法和用途
WO2018119207A1 (en) * 2016-12-21 2018-06-28 The Medical College Of Wisconsin, Inc. Synergistic inihibition of tumor cell proliferation induced by combined treatment of metformin compounds and iron chelators
KR101859922B1 (ko) * 2017-02-07 2018-05-21 주식회사 온코크로스 클로페네신을 포함하는 대장암 증식 및 전이 억제용 조성물
JP6900067B2 (ja) * 2017-02-07 2021-07-07 オンコクロス カンパニー，リミテッド 癌の転移抑制および治療用組成物
CN106831776B (zh) * 2017-03-16 2018-12-07 河北科技大学 5,10-二氢吡啶并吡嗪并三嗪类化合物及其应用
EP3713573A1 (en) * 2017-11-23 2020-09-30 Deutsches Krebsforschungszentrum Iron chelators in tumor therapy
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN110585194A (zh) * 2019-10-12 2019-12-20 广州医科大学附属第五医院 倍半萜内酯类化合物在制备溶酶体自噬抑制剂以及抗癌药物中的应用
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN111849873A (zh) * 2020-07-30 2020-10-30 扬州大学 一种诱导鸡的胚胎干细胞自噬的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089809A1 (en) * 2001-05-04 2002-11-14 The Procter & Gamble Company Medicinal uses of hydrazones and hydrazines
WO2006055412A1 (en) 2004-11-19 2006-05-26 Shiva Biomedical, Llc Methods of treating erythropoietin-resistance
WO2007128820A1 (en) * 2006-05-09 2007-11-15 Novartis Ag Combination comprising an iron chelator and an anti-neoplastic agent and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233101A1 (fr) * 1986-01-13 1987-08-19 Ire-Celltarg S.A. Dérivés de vinblastine et composition pharmaceutique les contenant
US5480906A (en) * 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
IL121272A (en) * 1997-07-10 2000-06-01 Can Fite Technologies Ltd Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
WO2004069801A1 (en) * 2003-02-05 2004-08-19 Unisearch Limited Metal ion chelators and therapeutic use thereof
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
WO2009035534A2 (en) * 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
KR101208587B1 (ko) * 2009-06-24 2012-12-06 여오영 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
WO2014046589A1 (en) 2012-09-21 2014-03-27 Vivolux Ab Means and method for treating solid tumours

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089809A1 (en) * 2001-05-04 2002-11-14 The Procter & Gamble Company Medicinal uses of hydrazones and hydrazines
WO2006055412A1 (en) 2004-11-19 2006-05-26 Shiva Biomedical, Llc Methods of treating erythropoietin-resistance
WO2007128820A1 (en) * 2006-05-09 2007-11-15 Novartis Ag Combination comprising an iron chelator and an anti-neoplastic agent and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pharmazie. 1987.09. Vol.42, No.10, pp 664-666*

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10386983B2 (en) 2014-12-31 2019-08-20 Tsinghua University Electrostatic sensing device
KR20250178249A (ko) 2024-06-17 2025-12-26 서울대학교산학협력단 Vlx600을 포함하는 항균 또는 항진균용 조성물 및 세균 또는 진균 감염증의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
MX2013010770A (es) 2014-03-27
IL228411A (en) 2016-12-29
KR20140017619A (ko) 2014-02-11
TR201809040T4 (tr) 2018-07-23
PL2688569T3 (pl) 2018-09-28
DK2688569T3 (en) 2018-08-06
EP2688569B1 (en) 2018-05-30
BR112013024211A2 (pt) 2016-12-20
EA025180B1 (ru) 2016-11-30
EA201391286A1 (ru) 2014-03-31
JP2014508804A (ja) 2014-04-10
WO2012128689A1 (en) 2012-09-27
JP6064215B2 (ja) 2017-02-01
SG193494A1 (en) 2013-10-30
HUE039021T2 (hu) 2018-12-28
US10022380B2 (en) 2018-07-17
ZA201307036B (en) 2014-05-28
ES2681703T3 (es) 2018-09-14
PT2688569T (pt) 2018-08-06
US20170348317A1 (en) 2017-12-07
CA2830081C (en) 2020-09-22
CA2830081A1 (en) 2012-09-27
AU2012231814B2 (en) 2016-06-09
AU2012231814A1 (en) 2013-09-26
EP2688569A4 (en) 2014-09-10
EP2688569A1 (en) 2014-01-29
SG10201605083SA (en) 2016-08-30
IL228411A0 (en) 2013-12-31
CN103547268B (zh) 2017-02-22
US20140073645A1 (en) 2014-03-13
BR112013024211B1 (pt) 2020-12-15
CN103547268A (zh) 2014-01-29

Similar Documents

Publication Publication Date Title
KR101937279B1 (ko) 고형 종양의 치료 방법
US9844522B2 (en) Niclosamide and its derivatives for use in the treatment of solid tumors
KR20200112897A (ko) mTOR 억제제, 약물 조성물 및 이의 응용
Ye et al. Anti-tumor activity and relative mechanism of ethanolic extract of Marsdenia tenacissima (Asclepiadaceae) against human hematologic neoplasm in vitro and in vivo
Yao et al. Licochalcone A, a natural inhibitor of c-Jun N-terminal kinase 1
Su et al. Blocking Parkin/PINK1-mediated mitophagy sensitizes hepatocellular carcinoma cells to sanguinarine-induced mitochondrial apoptosis
Gan et al. Digitoxin inhibits HeLa cell growth through the induction of G2/M cell cycle arrest and apoptosis in vitro and in vivo
Beberok et al. The role of MITF and Mcl-1 proteins in the antiproliferative and proapoptotic effect of ciprofloxacin in amelanotic melanoma cells: In silico and in vitro study
Luo et al. Potent antitumor activity of 10-methoxy-9-nitrocamptothecin
Hui et al. Fusaricide is a novel iron chelator that induces apoptosis through activating caspase-3
Pang et al. Ethyl ferulate suppresses esophageal squamous cell carcinoma tumor growth through inhibiting the mTOR signaling pathway
US20130065932A1 (en) Process for the isolation of organic compounds useful for the treatment of cancer
CN108578702B (zh) 一种稀有人参皂苷的混合物及其应用
JP2018501304A (ja) シナラ・スコリムスの滴定抽出物及びそれらの使用
Liu et al. Flubendazole inhibits cervical carcinoma by targeting DHODH to induce ferroptosis and mitophagy
US9138422B2 (en) Method of using antimycin A to downregulate Wnt/b-catenin pathway to treat gefitinib resistant cancer
Neumann-Mufweba et al. The diaryl-imidazopyridazine anti-plasmodial compound, MMV652103, exhibits anti-breast cancer activity
HK1191561A (en) Treatment of solid tumours
Yao et al. Design, synthesis and biological assessment of erlotinib-1, 2, 3-triazole derivatives for anticancer applications
HK1191561B (en) Treatment of solid tumours
Owadh et al. Forty micromole hydroxychloroquine enhanced cytotoxic effect of doxorubicin against laryngeal cancer cell line HEp-2
Yang et al. ZL11n is a novel nitric oxide-releasing derivative of farnesylthiosalicylic acid that induces apoptosis in human hepatoma HepG2 cells via MAPK/mitochondrial pathways
RU2429839C1 (ru) Средство, предотвращающее трансформацию нормальных клеток млекопитающих в опухолевые
KR100812032B1 (ko) 3,4-디히드로이소퀴놀리늄 염 유도체를 포함하는 항암제
CN107243079A (zh) 一种含大黄酸的药物组合物及其在制备抗肿瘤药物中的应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20211210

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20221212

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8